Frontera Therapeutics

Frontera Therapeutics is an international innovative gene therapy drug research and development and production company. Its R&D center is located in Boston, USA, with clinical operations and GMP production bases in Shanghai and Suzhou, China. The company has established an innovative recombinant adeno-associated virus (AAV) gene expression system platform aimed at optimizing innovative, clinically validated AAV vectors to enhance the safety and efficacy of gene therapy products. Frontera Therapeutics has also built a 500L scaled GMP production system, with the capacity to meet the medication needs of patients with different clinical indications. The company's R&D pipeline covers disease areas such as rare ophthalmic diseases, chronic diseases, blood disorders, neuromuscular, and metabolic diseases, offering significant market potential. Frontera Therapeutics is committed to providing high-quality, affordable gene therapy drugs for patients with rare diseases and chronic conditions worldwide.